• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC.

作者信息

Nagasaka Misako, Ou Sai-Hong Ignatius

机构信息

Karmanos Cancer Institute, School of Medicine, Wayne State University, Detroit, Michigan; Division of Neurology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.

Division of Hematology/Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California.

出版信息

J Thorac Oncol. 2021 Apr;16(4):532-536. doi: 10.1016/j.jtho.2020.12.021.

DOI:10.1016/j.jtho.2020.12.021
PMID:33781444
Abstract
摘要

相似文献

1
Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC.对于晚期ALK重排的非小细胞肺癌患者，洛拉替尼应被视为首选的一线治疗方案。
J Thorac Oncol. 2021 Apr;16(4):532-536. doi: 10.1016/j.jtho.2020.12.021.
2
Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC.对于晚期ALK重排的非小细胞肺癌患者，不应将劳拉替尼视为首选的一线治疗方案。
J Thorac Oncol. 2021 Apr;16(4):528-531. doi: 10.1016/j.jtho.2020.12.022.
3
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.劳拉替尼用于治疗具有ALK或ROS1重排的非小细胞肺癌：一项国际多中心、开放标签、单臂首次人体1期试验。
Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23.
4
First macrocyclic 3-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib.首个用于治疗 ALK/ROS1 癌症的三代大环ALK 抑制剂：洛拉替尼的临床和设计策略更新。
Eur J Med Chem. 2017 Jul 7;134:348-356. doi: 10.1016/j.ejmech.2017.04.032. Epub 2017 Apr 13.
5
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.洛拉替尼治疗 ALK 阳性非小细胞肺癌患者的疗效：一项全球性 2 期研究结果。
Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6.
6
Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.洛拉替尼在先前酪氨酸激酶抑制剂治疗失败的伴有ALK 或 ROS1 重排的韩国非小细胞肺癌患者中的疗效和安全性。
Clin Lung Cancer. 2019 May;20(3):215-221. doi: 10.1016/j.cllc.2018.12.020. Epub 2018 Dec 31.
7
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.克唑替尼耐药 ROS1 突变揭示了 ROS1 和 ALK 重排肺癌的预测激酶抑制剂敏感性模型。
Clin Cancer Res. 2016 Dec 15;22(24):5983-5991. doi: 10.1158/1078-0432.CCR-16-0917. Epub 2016 Jul 11.
8
Second- and third-generation ALK inhibitors for non-small cell lung cancer.用于非小细胞肺癌的第二代和第三代ALK抑制剂。
J Hematol Oncol. 2016 Mar 8;9:19. doi: 10.1186/s13045-016-0251-8.
9
Lorlatinib Is Active in Drug-Resistant NSCLC.劳拉替尼在耐药性 NSCLC 中具有活性。
Cancer Discov. 2016 Aug;6(8):OF1. doi: 10.1158/2159-8290.CD-NB2016-087. Epub 2016 Jul 8.
10
First-line lorlatinib for advanced ALK-positive non-small-cell lung cancer.一线使用劳拉替尼治疗晚期ALK阳性非小细胞肺癌。
Lancet Respir Med. 2023 Apr;11(4):302-304. doi: 10.1016/S2213-2600(22)00488-X. Epub 2022 Dec 16.

引用本文的文献

1
Exploring cellular plasticity and resistance mechanisms in lung cancer: Innovations and emerging therapies.探索肺癌中的细胞可塑性和耐药机制：创新与新兴疗法
J Pharm Anal. 2025 May;15(5):101179. doi: 10.1016/j.jpha.2024.101179. Epub 2025 Jan 3.
2
Case report: Therapeutic response to lorlatinib in advanced large-cell neuroendocrine carcinoma of the lung and breast cancer: a heterochronous double malignancy perspective.病例报告：洛拉替尼治疗晚期肺大细胞神经内分泌癌和乳腺癌的疗效：异时性双原发恶性肿瘤视角
Front Pharmacol. 2024 Dec 10;15:1413897. doi: 10.3389/fphar.2024.1413897. eCollection 2024.
3
Locally advanced/metastatic non-small-cell lung cancer in Lebanon: focus on ALK tyrosine kinase inhibitors.
黎巴嫩局部晚期/转移性非小细胞肺癌：聚焦于ALK酪氨酸激酶抑制剂
Future Oncol. 2025 Jan;21(1):127-137. doi: 10.1080/14796694.2024.2421737. Epub 2024 Nov 15.
4
Current status of molecular diagnostics for lung cancer.肺癌分子诊断的现状
Explor Target Antitumor Ther. 2024;5(3):742-765. doi: 10.37349/etat.2024.00244. Epub 2024 Jun 27.
5
ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies.癌症中的ALK抑制剂：耐药机制与治疗管理策略
Cancer Drug Resist. 2024 May 23;7:20. doi: 10.20517/cdr.2024.25. eCollection 2024.
6
The Riddle of the Sphinx: Progress in Leptomeningeal Metastasis of Non-Small Cell Lung Cancer.斯芬克斯之谜：非小细胞肺癌软脑膜转移的研究进展
Clin Med Insights Oncol. 2023 Oct 30;17:11795549231205206. doi: 10.1177/11795549231205206. eCollection 2023.
7
Mutation status analysis of 58 patients with advanced ALK fusion gene positive non small cell lung cancer.58 例晚期 ALK 融合基因阳性非小细胞肺癌患者的突变状态分析。
BMC Pulm Med. 2023 Sep 1;23(1):319. doi: 10.1186/s12890-023-02618-x.
8
Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced - or -Rearranged NSCLC: A Brief Report.洛拉替尼在晚期或重排非小细胞肺癌患者中的耐受性及与临床结局的关联：简要报告
JTO Clin Res Rep. 2023 Jun 30;4(8):100546. doi: 10.1016/j.jtocrr.2023.100546. eCollection 2023 Aug.
9
Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial.恩沃利单抗对比克唑替尼用于初治 ALK 阳性非小细胞肺癌：一项随机、多中心、开放标签、III 期临床试验。
Signal Transduct Target Ther. 2023 Aug 14;8(1):301. doi: 10.1038/s41392-023-01538-w.
10
Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced -Positive NSCLC.一线劳拉替尼对比克唑替尼治疗晚期ALK阳性非小细胞肺癌的随机3期CROWN研究的亚洲亚组分析
JTO Clin Res Rep. 2023 Mar 11;4(5):100499. doi: 10.1016/j.jtocrr.2023.100499. eCollection 2023 May.